BioSpace News Archive

Drug Development

AbbVie Touts Subgroup Data in Phase II Atrial Fibrillation Miss

AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.

November 8, 2022
·
2 min read
·
Tristan Manalac
Policy

FDA Cites ‘Uncertainties’ in Veru’s COVID-19 Antiviral Data Ahead of Adcomm

The FDA presented briefing documents Monday outlining what it called “uncertainties” in the data presented by Veru regarding its COVID-19 antiviral. An advisory committee will meet Wednesday.

November 8, 2022
·
3 min read
·
Alex Keown
Business

Sanofi Secures Access to Salipro’s Protein Stabilization Tech in R&D Deal

Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech to develop therapeutic antibodies or small molecules that target membrane proteins.

November 8, 2022
·
2 min read
·
Mark Terry
Drug Development

BioMarin Faces Potential 3-Month Delay for Hemophilia A Gene Therapy (Updated)

A request for additional data may cause a 3-month delay for potential approval of BioMarin Pharmaceutical’s hemophilia A gene therapy.

November 8, 2022
·
2 min read
·
Alex Keown
Drug Development

80% of Patients in Investigational Breast Cancer Vaccine Trial Alive after 10 Years

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

November 8, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Juvena Nets $41M to Demystify the Therapeutic Potential of Secreted Proteins

Juvena Therapeutics pulled in $41 million in Series A financing to advance research into the therapeutic potential of secreted proteins to target chronic and age-related diseases.

November 8, 2022
·
3 min read
·
Rosemary Scott
Business

Sanofi Reaffirms Commitment to AI Drug Discovery with $1.2B Insilico Pact

Sanofi entered into a partnership with Insilico Medicine to develop drugs for up to six targets. The deal is worth a potential $1.2 billion.

November 8, 2022
·
2 min read
·
Mark Terry
Drug Development

GSK Plans Phase III Trial for Hepatitis B Drug Despite Data Dropoff (Updated)

GSK is planning a Phase III trial evaluating bepirovirsen as a potential functional cure for chronic hepatitis B infection, despite the most recently released data appearing less robust than the interim analyses.

November 8, 2022
·
2 min read
·
Alex Keown
Sequana Medical to present at Jefferies 2022 London Healthcare Conference

Sequana Medical NV announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to 17 November 2022.

November 8, 2022
·
3 min read
SciBase announces collaboration to detect skin barrier dysfunction in infants

SciBase Holding AB announced that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

November 8, 2022
·
3 min read